Dr Reddy s acquires trademark rights of breast cancer drug Primcyv from Pfizer to use in India

Hyderabad, Jan. 13 (PTI) Dr. Reddy's Laboratories Ltd. on Friday announced that it has acquired the trademark rights of the breast cancer drug Primcyv from Pfizer ProductsIndia Pvt Ltd for use in the Indian market. Dr. Reddy's Laboratories Ltd. on Friday announced that it has acquired the trademark rights of the breast cancer drug Primcyv from Pfizer ProductsIndia Pvt Ltd for use in the Indian market. Primcyv is a targeted therapy containing the active constituent palbociclib, a first-in-class CDK 4/6 inhibitor indicated in combination with an aromatase inhibitor for the first-line treatment of adult patients with HR+, HER2 metastatic breast cancer, said a press release from the city-based drug-maker. Since May 2022, Dr. Reddy's has been marketing the drug in collaboration with Pfizer Products India under the brandname Primcyv in India. The drug comes in the form of hard capsules in strengths of 75 mg, 100 mg and 125 mg, it further said. Following the trademark rights acquisition, Dr. Reddy's will manufacture the Active Pharmaceutical Ingredient (API) and finished drug at its state-of-the-art facilities approved by the United States Food and Drug Administration (USFDA). Dr. Reddy's is amongst select companies in the world to have conducted a bioequivalence study and received tentative approval from the USFDA for palbociclib. The in-house product will be retailed in the Indian market at a reduction of 85 per cent from the current MRP to increase affordability and access to palbociclib. Dr. Reddy's plans to roll out a unique Patient Assistance Programme to support long-term therapy of the patients on Primcyv, it added

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!